Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.
Am J Nephrol
; 33(3): 269-76, 2011.
Article
en En
| MEDLINE
| ID: mdl-21372562
ABSTRACT
BACKGROUND/AIMS:
Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats.METHODS:
Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined.RESULTS:
Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group.CONCLUSION:
These results demonstrate that terlipressin can inhibit the development of CIN.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vasoconstrictores
/
Lipresina
/
Vasopresinas
/
Medios de Contraste
/
Lesión Renal Aguda
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Am J Nephrol
Año:
2011
Tipo del documento:
Article
País de afiliación:
Turquía